6Z3Y
| |
8WBV
| |
8WBU
| |
7CLZ
| |
5CM4
| Crystal structure of human Frizzled 4 Cysteine-Rich Domain (CRD) | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Frizzled-4 | Authors: | Ke, J, Parker, N, Gu, X, Zhang, C, Melcher, K, Xu, H.E. | Deposit date: | 2015-07-16 | Release date: | 2015-08-12 | Last modified: | 2024-11-06 | Method: | X-RAY DIFFRACTION (2.4 Å) | Cite: | Structural basis of the Norrin-Frizzled 4 interaction. Cell Res., 25, 2015
|
|
3BQD
| Doubling the Size of the Glucocorticoid Receptor Ligand Binding Pocket by Deacylcortivazol | Descriptor: | 1-[(1R,2R,3aS,3bS,10aR,10bS,11S,12aS)-1,11-dihydroxy-2,5,10a,12a-tetramethyl-7-phenyl-1,2,3,3a,3b,7,10,10a,10b,11,12,12a-dodecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-yl]-2-hydroxyethanone, Glucocorticoid receptor, Nuclear receptor coactivator 1 | Authors: | Xu, H.E. | Deposit date: | 2007-12-20 | Release date: | 2008-01-15 | Last modified: | 2023-08-30 | Method: | X-RAY DIFFRACTION (2.5 Å) | Cite: | Doubling the size of the glucocorticoid receptor ligand binding pocket by deacylcortivazol. Mol.Cell.Biol., 28, 2008
|
|
3BUS
| Crystal Structure of RebM | Descriptor: | Methyltransferase, S-ADENOSYL-L-HOMOCYSTEINE | Authors: | McCoy, J.G, Singh, S, Bingman, C.A, Thorson, J.S, Phillips Jr, G.N. | Deposit date: | 2008-01-03 | Release date: | 2008-03-25 | Last modified: | 2024-10-30 | Method: | X-RAY DIFFRACTION (2.65 Å) | Cite: | Structure and mechanism of the rebeccamycin sugar 4'-O-methyltransferase RebM. J.Biol.Chem., 283, 2008
|
|
8HQN
| Activation mechanism of GPR132 by 9(S)-HODE | Descriptor: | (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid, Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2, Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1, ... | Authors: | Wang, J.L, Ding, J.H, Sun, J.P, Yu, X. | Deposit date: | 2022-12-13 | Release date: | 2023-10-11 | Last modified: | 2024-11-06 | Method: | ELECTRON MICROSCOPY (3 Å) | Cite: | Functional screening and rational design of compounds targeting GPR132 to treat diabetes. Nat Metab, 5, 2023
|
|
8HQM
| Activation mechanism of GPR132 by NPGLY | Descriptor: | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2, Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1, Guanine nucleotide-binding protein G(i) subunit alpha-1, ... | Authors: | Wang, J.L, Ding, J.H, Sun, J.P, Yu, X. | Deposit date: | 2022-12-13 | Release date: | 2023-10-11 | Last modified: | 2024-10-23 | Method: | ELECTRON MICROSCOPY (2.95 Å) | Cite: | Functional screening and rational design of compounds targeting GPR132 to treat diabetes. Nat Metab, 5, 2023
|
|
8HVI
| Activation mechanism of GPR132 by compound NOX-6-7 | Descriptor: | 3-methyl-5-[(4-oxidanylidene-4-phenyl-butanoyl)amino]-1-benzofuran-2-carboxylic acid, Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2, Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1, ... | Authors: | Wang, J.L, Ding, J.H, Sun, J.P, Yu, X. | Deposit date: | 2022-12-26 | Release date: | 2023-10-11 | Last modified: | 2024-10-16 | Method: | ELECTRON MICROSCOPY (3.04 Å) | Cite: | Functional screening and rational design of compounds targeting GPR132 to treat diabetes. Nat Metab, 5, 2023
|
|
8HQE
| Cryo-EM structure of the apo-GPR132-Gi | Descriptor: | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2, Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1, Guanine nucleotide-binding protein G(i) subunit alpha-1, ... | Authors: | Wang, J.L, Ding, J.H, Sun, J.P, Yu, X. | Deposit date: | 2022-12-13 | Release date: | 2023-10-11 | Last modified: | 2024-10-16 | Method: | ELECTRON MICROSCOPY (2.97 Å) | Cite: | Functional screening and rational design of compounds targeting GPR132 to treat diabetes. Nat Metab, 5, 2023
|
|
8WKN
| Cryo-EM structure of DSR2-DSAD1 | Descriptor: | SIR2-like domain-containing protein, SPbeta prophage-derived uncharacterized protein YotI | Authors: | Zhang, H, Li, Z, Li, X.Z. | Deposit date: | 2023-09-28 | Release date: | 2024-05-01 | Last modified: | 2024-05-08 | Method: | ELECTRON MICROSCOPY (3.4 Å) | Cite: | Insights into the modulation of bacterial NADase activity by phage proteins. Nat Commun, 15, 2024
|
|
6OT0
| Structure of human Smoothened-Gi complex | Descriptor: | 17-[3-(3,3-DIMETHYL-OXIRANYL)-1-METHYL-PROPYL]-10,13-DIMETHYL-2,3,4,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-1H-CYC LOPENTA[A]PHENANTHREN-3-OL, Fab heavy chain, Fab light chain, ... | Authors: | Qi, X, Li, X. | Deposit date: | 2019-05-02 | Release date: | 2019-06-12 | Last modified: | 2024-11-13 | Method: | ELECTRON MICROSCOPY (3.84 Å) | Cite: | Cryo-EM structure of oxysterol-bound human Smoothened coupled to a heterotrimeric Gi. Nature, 571, 2019
|
|
8XKN
| Cryo-EM structure of tail tube protein | Descriptor: | a protein | Authors: | Zhang, H, Li, Z, Li, X.Z. | Deposit date: | 2023-12-23 | Release date: | 2024-05-01 | Last modified: | 2024-05-08 | Method: | ELECTRON MICROSCOPY (3.11 Å) | Cite: | Insights into the modulation of bacterial NADase activity by phage proteins. Nat Commun, 15, 2024
|
|
6PBK
| |
6UQC
| Mouse IgG2a Bispecific Fc | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... | Authors: | Wang, F, Tsai, J.C, Davis, J.H, West, S.M, Strop, P. | Deposit date: | 2019-10-18 | Release date: | 2020-01-01 | Last modified: | 2024-11-13 | Method: | X-RAY DIFFRACTION (1.87 Å) | Cite: | Design and characterization of mouse IgG1 and IgG2a bispecific antibodies for use in syngeneic models. Mabs, 12, 2019
|
|
7M8W
| XFEL crystal structure of the prostaglandin D2 receptor CRTH2 in complex with 15R-methyl-PGD2 | Descriptor: | 15R-methyl-prostaglandin D2, CITRATE ANION, Prostaglandin D2 receptor 2, ... | Authors: | Shiriaeva, A, Han, G.W, Cherezov, V. | Deposit date: | 2021-03-30 | Release date: | 2021-08-25 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (2.61 Å) | Cite: | Molecular basis for lipid recognition by the prostaglandin D 2 receptor CRTH2. Proc.Natl.Acad.Sci.USA, 118, 2021
|
|
8K98
| Cryo-EM structure of DSR2-TTP | Descriptor: | a protein | Authors: | Zhang, H, Li, Z, Li, X.Z. | Deposit date: | 2023-07-31 | Release date: | 2024-05-01 | Last modified: | 2024-05-08 | Method: | ELECTRON MICROSCOPY (2.9 Å) | Cite: | Insights into the modulation of bacterial NADase activity by phage proteins. Nat Commun, 15, 2024
|
|
8K9A
| Cryo-EM structure of DSR2-DSAD1 state 2 | Descriptor: | SIR2-like domain-containing protein, SPbeta prophage-derived uncharacterized protein YotI | Authors: | Zhang, H, Li, Z, Li, X.Z. | Deposit date: | 2023-07-31 | Release date: | 2024-05-01 | Last modified: | 2024-05-08 | Method: | ELECTRON MICROSCOPY (3.9 Å) | Cite: | Insights into the modulation of bacterial NADase activity by phage proteins. Nat Commun, 15, 2024
|
|
5UGC
| Crystal structure of the EGFR kinase domain (L858R, T790M, V948R) in complex with a covalent inhibitor N-[(3R,4R)-4-fluoro-1-{6-[(3-methoxy-1-methyl-1H-pyrazol-4-yl)amino]-9-methyl-9H-purin-2-yl}pyrrolidin-3-yl]propanamide | Descriptor: | 1,2-ETHANEDIOL, Epidermal growth factor receptor, GLYCEROL, ... | Authors: | Gajiwala, K.S, Ferre, R.A. | Deposit date: | 2017-01-08 | Release date: | 2017-03-22 | Last modified: | 2024-11-13 | Method: | X-RAY DIFFRACTION (1.58 Å) | Cite: | Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR. J. Med. Chem., 60, 2017
|
|
7SHU
| IgE-Fc in complex with omalizumab variant C02 | Descriptor: | 1,2-ETHANEDIOL, 2-acetamido-2-deoxy-beta-D-glucopyranose, Immunoglobulin heavy constant epsilon, ... | Authors: | Pennington, L.F, Jardetzky, T.J, Kleinboelting, S. | Deposit date: | 2021-10-11 | Release date: | 2021-12-15 | Last modified: | 2024-11-13 | Method: | X-RAY DIFFRACTION (2.75 Å) | Cite: | Directed evolution of and structural insights into antibody-mediated disruption of a stable receptor-ligand complex. Nat Commun, 12, 2021
|
|
7SHT
| |
5UG9
| Crystal structure of the EGFR kinase domain (L858R, T790M, V948R) in complex with a covalent inhibitor N-[(3R,4R)-4-fluoro-1-{6-[(3-methoxy-1-methyl-1H-pyrazol-4-yl)amino]-9-(propan-2-yl)-9H-purin-2-yl}pyrrolidin-3-yl]propanamide | Descriptor: | 1,2-ETHANEDIOL, Epidermal growth factor receptor, GLYCEROL, ... | Authors: | Gajiwala, K.S, Ferre, R.A. | Deposit date: | 2017-01-07 | Release date: | 2017-03-22 | Last modified: | 2024-10-30 | Method: | X-RAY DIFFRACTION (1.33 Å) | Cite: | Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR. J. Med. Chem., 60, 2017
|
|
5UGA
| Crystal structure of the EGFR kinase domain (L858R, T790M, V948R) in complex with 4-(4-{[2-{[(3S)-1-acetylpyrrolidin-3-yl]amino}-9-(propan-2-yl)-9H-purin-6-yl]amino}phenyl)-1-methylpiperazin-1-ium | Descriptor: | 4-(4-{[2-{[(3S)-1-acetylpyrrolidin-3-yl]amino}-9-(propan-2-yl)-9H-purin-6-yl]amino}phenyl)-1-methylpiperazin-1-ium, Epidermal growth factor receptor, GLYCEROL, ... | Authors: | Gajiwala, K.S, Ferre, R.A. | Deposit date: | 2017-01-07 | Release date: | 2017-03-22 | Last modified: | 2024-03-06 | Method: | X-RAY DIFFRACTION (1.82 Å) | Cite: | Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR. J. Med. Chem., 60, 2017
|
|
5UGB
| |